It will be a turbulent ride, but patient investors might come out of it much richer.

If biotech funding continues to increase this year, Danaher could benefit.

Legend Biotech ( LEGN +18.42%) was one of the healthier healthcare stocks on the market as the trading week kicked off on ...

We'll know more about the company's medium-term prospects by the end of the year.

After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a path forward ...

Introducing CPC Biotech - one brand uniting critical fluid management components New brand unites CPC’s Biopharma connector ...

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced it has received the ...

The deal for Kelonia Therapeutics is valued at $3.25 billion upfront.

Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech ...

The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...